Clinical trial
Ampligen in Chronic Fatigue Syndrome
NCT00215813 · AIM ImmunoTech Inc., Industry · Temporarily not available
Key facts
| NCT number | NCT00215813 |
|---|---|
| Title | Ampligen in Chronic Fatigue Syndrome |
| Official title | An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN®) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS) |
| Lead sponsor | AIM ImmunoTech Inc., Industry |
| Status | Temporarily not available |
| Study type | Expanded Access |
| Conditions | Chronic Fatigue Syndrome |
| Intervention type | Drug |
| Interventions | Poly I: Poly C12U (Rintatolimod) |
| First posted | Sep 22, 2005 |
| Last update posted | Oct 29, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: